SG11202110911RA - Improved competitive ligand binding assays - Google Patents
Improved competitive ligand binding assaysInfo
- Publication number
- SG11202110911RA SG11202110911RA SG11202110911RA SG11202110911RA SG11202110911RA SG 11202110911R A SG11202110911R A SG 11202110911RA SG 11202110911R A SG11202110911R A SG 11202110911RA SG 11202110911R A SG11202110911R A SG 11202110911RA SG 11202110911R A SG11202110911R A SG 11202110911RA
- Authority
- SG
- Singapore
- Prior art keywords
- ligand binding
- binding assays
- competitive ligand
- improved competitive
- improved
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/40—Rare earth chelates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846872P | 2019-05-13 | 2019-05-13 | |
| US201962859914P | 2019-06-11 | 2019-06-11 | |
| PCT/US2020/032476 WO2020231992A1 (en) | 2019-05-13 | 2020-05-12 | Improved competitive ligand binding assays |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110911RA true SG11202110911RA (en) | 2021-10-28 |
Family
ID=70919175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110911RA SG11202110911RA (en) | 2019-05-13 | 2020-05-12 | Improved competitive ligand binding assays |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200363400A1 (en) |
| EP (1) | EP3969908A1 (en) |
| JP (1) | JP7541534B2 (en) |
| KR (1) | KR20220007586A (en) |
| CN (1) | CN113785203A (en) |
| AU (1) | AU2020275406A1 (en) |
| CA (1) | CA3135004A1 (en) |
| IL (1) | IL287913A (en) |
| MX (1) | MX2021013519A (en) |
| SG (1) | SG11202110911RA (en) |
| WO (1) | WO2020231992A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116601491A (en) * | 2020-12-18 | 2023-08-15 | 安托斯治疗股份有限公司 | Method for detecting anti-drug antibodies against factor XI and/or factor XIA antibodies |
| CN114047343B (en) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | Immunogenicity analysis kit of double-tolerance anti-IgE monoclonal antibody medicine and use method and application thereof |
| CN116699147A (en) * | 2023-08-04 | 2023-09-05 | 军科正源（北京）药物研究有限责任公司 | Method for detecting total IgE content and related kit |
| CN118275703B (en) * | 2024-06-03 | 2024-08-23 | 军科正源（北京）药物研究有限责任公司 | Method for detecting neutralizing antibody of anti-lymphocyte activating gene 3 antibody drug |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1621554E (en) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5958339A (en) * | 1992-08-31 | 1999-09-28 | Clinical Diagnostic Systems, Inc. | Format for immunoassay in thin film |
| DK0698097T3 (en) | 1993-04-29 | 2001-10-08 | Unilever Nv | Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| JP3727317B2 (en) | 2002-03-08 | 2005-12-14 | エイエスエムエル ネザランドズ ベスローテン フエンノートシャップ | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| BRPI0712224B8 (en) | 2006-06-02 | 2021-05-25 | Regeneron Pharma | high affinity antibodies to the human IL-6 receptor and pharmaceutical compositions |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| NZ583019A (en) | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| WO2009022001A1 (en) | 2007-08-16 | 2009-02-19 | Novartis Ag | Improvement of drug tolerance in immunogenicity testing |
| JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
| JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
| JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
| AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
| PL3354280T3 (en) | 2010-10-06 | 2021-02-08 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| AR087329A1 (en) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | HUMAN ANTIBODIES AGAINST PROTEIN 3 OF HUMAN ANGIOPOIETIN TYPE |
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| CA2853917A1 (en) | 2011-12-19 | 2013-06-27 | F. Hoffmann-La Roche Ag | Method for the detection of free binding partner of a multispecific binder |
| JP6113756B2 (en) | 2012-01-23 | 2017-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Stabilized formulation containing anti-ANG2 antibody |
| JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
| TW201843172A (en) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
| CN104540852B (en) | 2012-08-13 | 2018-10-02 | 瑞泽恩制药公司 | Anti- PCSK9 antibody with pH- dependence binding characteristics |
| JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
| JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
| JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
| TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
| KR20150127591A (en) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 antagonists and uses thereof |
| TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
| CN105765386B (en) * | 2013-10-31 | 2019-07-16 | 瑞泽恩制药公司 | For detecting the competitive ligand binding assays of neutralizing antibody |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| ES2736126T3 (en) | 2014-03-11 | 2019-12-26 | Regeneron Pharma | ANTI-EGFRVIII antibodies and uses thereof |
| TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
| WO2015171523A1 (en) | 2014-05-05 | 2015-11-12 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
| WO2016044337A1 (en) | 2014-09-16 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| EP3652539A4 (en) * | 2017-07-10 | 2021-03-31 | Rambam Med-Tech Ltd. | Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine |
| EP3717916A1 (en) * | 2017-11-29 | 2020-10-07 | H. Hoffnabb-La Roche Ag | Target interference suppressed anti-drug antibody assay |
-
2020
- 2020-05-12 SG SG11202110911RA patent/SG11202110911RA/en unknown
- 2020-05-12 WO PCT/US2020/032476 patent/WO2020231992A1/en unknown
- 2020-05-12 JP JP2021564504A patent/JP7541534B2/en active Active
- 2020-05-12 AU AU2020275406A patent/AU2020275406A1/en active Pending
- 2020-05-12 KR KR1020217032422A patent/KR20220007586A/en unknown
- 2020-05-12 US US16/872,767 patent/US20200363400A1/en active Pending
- 2020-05-12 EP EP20729485.1A patent/EP3969908A1/en active Pending
- 2020-05-12 CA CA3135004A patent/CA3135004A1/en active Pending
- 2020-05-12 CN CN202080033465.0A patent/CN113785203A/en active Pending
- 2020-05-12 MX MX2021013519A patent/MX2021013519A/en unknown
-
2021
- 2021-11-08 IL IL287913A patent/IL287913A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022532503A (en) | 2022-07-15 |
| KR20220007586A (en) | 2022-01-18 |
| MX2021013519A (en) | 2021-12-10 |
| US20200363400A1 (en) | 2020-11-19 |
| CN113785203A (en) | 2021-12-10 |
| JP7541534B2 (en) | 2024-08-28 |
| AU2020275406A1 (en) | 2021-11-18 |
| WO2020231992A1 (en) | 2020-11-19 |
| CA3135004A1 (en) | 2020-11-19 |
| EP3969908A1 (en) | 2022-03-23 |
| IL287913A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277343A (en) | Cd47 binding agents | |
| GB201802201D0 (en) | Binding agents | |
| IL287913A (en) | Improved competitive ligand binding assays | |
| SG11202009802WA (en) | Colocalization-by-linkage sandwich assays | |
| EP4076343C0 (en) | Retinol-based serum | |
| EP3794937C0 (en) | Binding machine | |
| GB201812487D0 (en) | C-Met binding agents | |
| EP3848537C0 (en) | Binding machine | |
| IL304317A (en) | Tgf-beta-rii binding proteins | |
| PL3848292T3 (en) | Binding machine | |
| EP3587707C0 (en) | Binding machine | |
| LT3587708T (en) | Binding machine | |
| GB201900552D0 (en) | A mixer | |
| EP3782458C0 (en) | Binding machine | |
| EP3782461C0 (en) | Binding machine | |
| EP4069409C0 (en) | Mixer | |
| GB201912657D0 (en) | Binding members | |
| ZA201901889B (en) | Ligand binding assay for detecting gibberellins | |
| GB201904437D0 (en) | Phase determination | |
| SG11202111474SA (en) | Novel ligand assays | |
| GB201709379D0 (en) | Humanised ADAMTS13 binding antibodies | |
| IL287629A (en) | Assays | |
| PL3782461T3 (en) | Binding machine | |
| GB201910899D0 (en) | Binding members | |
| GB201913937D0 (en) | Ligand Design |